Recent legal and regulatory developments could influence how innovative medicines are protected in Europe by changing the interaction between regulatory exclusivity, patent rights and generic market entry.

Merck has agreed to acquire biotechnology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening its oncology pipeline ahead of the upcoming patent expiry of its blockbuster drug, Keytruda.